Phase II Dose-finding Study of ASP4070 -A Randomized, Double-blind, Placebo-controlled, Dose-finding Study in Environmental Exposure Chamber in Patients With Cedar Pollinosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2018
At a glance
- Drugs ASP 4070 (Primary)
- Indications Allergic rhinoconjunctivitis; Tree pollen hypersensitivity
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 02 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Apr 2017 Status changed from not yet recruiting to recruiting.
- 02 Apr 2017 Status changed from planning to not yet recruiting.